Sujata Patil, PhD

Associate Attending Biostatistician

Sujata Patil, PhD

Associate Attending Biostatistician

Office Phone

646-888-8254

E-mail

patils@mskcc.org

Current Research Interests

Dr. Patil’s biostatistical research interests are in longitudinal data analysis, clinical trial design, the analysis of incomplete data, survival analysis, measurement error models, and Bayesian methods.   Dr. Patil uses these methods in her clinical collaborations with oncologists and surgeons in the Genitourinary, Breast, and Colorectal Surgery Services.  In recent publications, she has examined stage migration in metastatic renal cell carcinoma over the last four decades. In ongoing work, Dr. Patil is developing methodology that can be used to investigate the relationship between two or more longitudinal biomarkers as predictors of disease outcome.  Recently, she has been involved in developing efficient clinical trial designs for therapies that target brain metastases.   Dr. Patil regularly lectures for the Department of Surgery Clinical Research Methods course and for the Department of Medicine K30 Clinical Trial Design Symposium.

Education

University of Michigan

Publications

Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2011 Feb;22(2):295-300. Epub 2010 Jul 25. [PubMed Abstract]

Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010 Jan 15;116(2):347-54. [PubMed Abstract]

Bosl GJB, Patil SM.  Carboplatin in clinical stage I seminoma: too much and too little at the same time.  J Clin Oncol. 2011 Jan 31. [PubMed Abstract] 

Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ.  Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib versus interferon-alfa.  British Journal of Cancer. [in press]

Patil SM, Shope JT, Raghunathan TE, Bingham CR. The role of personality characteristics in young adult driving. Traffic Inj Prev. 2006 Dec;7(4):328-34. [PubMed Abstract]

Read more
1. Anderson DR, Patil SM, Kamina A, Penson DF, Peduzzi P, Concato J. Validation and modification of a staging system for evaluating prognosis in prostate cancer. Conn Med. 2000; 64(8):459-64. PubMed PMID: 10984970.
2.  Shope JT, Waller PF, Raghunathan TE, Patil S. Adolescent antecedents of high-risk driving behavior in young adulthood: substance use and parental influences. Accid Anal Prev. 2001;33(5):649­-58. PubMed PMID: 11491245.
3. Shope JT, Raghunathan TE, Patil SM. Examining trajectories of adolescent risk factors as predictors of subsequent high-risk driving behavior.  J Adolesc Health. 2003;32(3): 214-24. PubMed PMID: 12606115.
4. Gross SR, Jacoby K, Matheson DJ, Montgomery N, Patil SM. Exonerations in the United States 1989 through 2003. J Crim Law Criminol. 2005; 95(2): 523-60.
5. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006;42(7):907-14. PubMed PMID: 16511752.
6. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Reply to Robertson et al. Clin Infect Dis. 2006; 43:544-45.
7. Davis JA, McBride MG, Chrisant MR, Patil SM, Hanna BD, Paridon SM. Longitudinal assessment of cardiovascular exercise performance after pediatric heart transplantation. J Heart Lung Transplant. 2006;25(6):626-33. Epub 2006 May 2. PubMed PMID: 16730567.
8. Patil SM, Shope JT, Raghunathan TE, Bingham CR. The role of personality characteristics in young adult driving. Traffic Inj Prev. 2006 Dec;7(4):328-34. PubMed PMID: 17114089; PubMed Central PMCID: PMC1855292.
9. Feldman DR, Kondagunta GV, Ginsberg MS, Ishill N, Patil S, Cestaro J, Obbens  E, Sheinfeld J, Bosl GJ, Motzer RJ. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 2007 Oct;25(5):487-90. Epub 2007 May 23. PubMed PMID: 17520176.
10. Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, Susnik B, Giri D, Polo K, Patil S, Van Zee KJ. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007 Oct;14(10):2961-70. Epub 2007 Jun 12. PubMed PMID: 17562113.
11. Hurria A, Lichtman SM, Gardes J, Li D, Limaye S, Patil S, Zuckerman E, Tew W, Hamlin P, Abou-Alfa GK, Lachs M, Kelly E. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc. 2007 Oct;55(10):1604-8. Epub 2007 Aug 14. PubMed PMID: 17697101.
12. Chelliah A, Heydon KH, Zaoutis TE, Rettig SL, Dominguez TE, Lin R, Patil S, Feudtner C, St John KH, Bell LM, Coffin SE. Observational trial of antibiotic-coated central venous catheters in critically ill pediatric patients.  Pediatr Infect Dis J. 2007 Sep;26(9):816-20. PubMed PMID: 17721377.
13. Dang C, Patil SM.  Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. Letter in response to Gennari et al Journal of Clinical Oncology 2006;24: 3912-3918.  Breast Diseases: A Yearbook Quarterly 2007; 18(3): 305.
14. Fornier M, Rathkopf D, Shah M, Patil SM, O’Reilly E, Tse A, Hudis C, Kelsen DP, Schwartz.  Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors, CCR-07-1218 Version 2.  Clin Cancer Res. 2007;13(19): 5841-6. PMID: 17908977
15. McLaughlin SA, Ochoa-Frongia LM, Patil SM, Cody HS 3rd, Sclafani LM. Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy. J Am Coll Surg. 2008 Jan;206(1):76-82. Epub 2007 Oct 18. PubMed PMID: 18155571.
16. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008 Feb;51(2):147-53. Epub 2008 Jan 8. Erratum in: Dis Colon Rectum. 2008 May;51(5):620. PubMed PMID: 18180997.
17. Flynn LW, Park J, Patil SM, Cody HS 3rd, Port ER. Sentinel lymph node biopsy  is successful and accurate in male breast carcinoma. J Am Coll Surg. 2008 Apr;206(4):616-21. Epub 2008 Feb 21. PubMed PMID: 18387465.
18. Traina TA, Theodoulou M, Feigin K, Patil S, Tan KL, Edwards C, Dugan U, Norton L, Hudis C. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol. 2008 Apr 10;26(11):1797-802. PubMed PMID: 18398145.
19. Jathavedam A, Feldman DR, Ishill N, Turkula S, Patil S, Bosl GJ, Motzer RJ, Weinstock DM. Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biol Blood Marrow Transplant. 2008 May;14(5):595-600. PubMed PMID: 18410903.
20. Feldman DR, Kondagunta GV, Schwartz L, Patil S, Ishill N, DeLuca J, Russo P,  Motzer RJ. Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2008 Mar;6(1):25-30. PubMed PMID: 18501079.
21. Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L. Is the “10% rule” equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol. 2008 Oct;15(10):2728-33. Epub 2008 Aug 8. PubMed PMID: 18688679.
22. Zauderer M, Patil S, Hurria A. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat. 2009 Sep;117(1):205-10. Epub 2008 Jul 13. PubMed PMID: 18622739.
23. Rudloff U, Brogi E, Brockway JP, Goldberg JI, Cranor M, Wynveen CA, Nehhozina T, Reiner AS, Patil S, Van Zee KJ. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2009 Mar 15;115(6):1203-14.  Erratum in: Cancer. 2010 Apr 15;116(8):2064. PubMed PMID: 19170233.
24. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Mar;27(9):1432-9. Epub 2009 Feb 17. PubMed PMID: 19224847.
25. Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Port ER, Morrow M, Gemignani ML. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. Ann Surg Oncol. 2009 Jul;16(7):1952-8. Epub 2009 Apr 18. PubMed PMID: 19381724.
26. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009 Jul 10;27(20):3379-84. Epub 2009 Jun 1. PubMed PMID: 19487380.
27. Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ, Motzer RJ. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2010 Aug;28(4):523-8. Epub 2009 Jun 23. PubMed PMID: 19547919.
28. Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 2009 Oct;16(10):2705-10. Epub 2009 Jul 11. PubMed PMID: 19593632.
29. Hurria A, Li D, Hansen K, Patil S, Gupta R, Nelson C, Lichtman SM, Tew WP, Hamlin P, Zuckerman E, Gardes J, Limaye S, Lachs M, Kelly E. Distress in older patients with cancer. J Clin Oncol. 2009 Sep 10;27(26):4346-51. Epub 2009 Aug 3.  PubMed PMID: 19652074; PubMed Central PMCID: PMC2799049.
30. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009 Aug 15;15(16):5049-59. Epub 2009 Aug 11. PubMed PMID: 19671852.
31. Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin LX, Patil S, Reuter VE, Bosl GJ, Chaganti RS. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol. 2009 Nov 1;27(31):5240-7. Epub 2009 Sep 21. PubMed PMID: 19770384.
32. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010 Feb 1;28(4):628-33. Epub 2009 Oct 19. PubMed PMID: 19841327.
33. Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation. Cancer. 2010 Jan 15;116(2):347-54. PubMed PMID: 19921736.
34. Pugliese MS, Karam AK, Hsu M, Stempel MM, Patil SM, Ho AY, Traina TA, Van Zee KJ, Cody HS 3rd, Morrow M, Gemignani ML. Predictors of completion axillary lymph  node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer. Ann Surg Oncol. 2010 Apr;17(4):1063-8. Epub 2009 Dec 22. PubMed PMID: 20033325.
35. Morris PG, Poznak CV, Modi S, Mak AF, Patil S, Larson S, Hudis CA, Divgi C, Grewal RK. Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. Clin Breast Cancer. 2010 Feb;10(1):33-9. PubMed PMID: 20133256.
36. Port ER, Patil S, Stempel M, Morrow M, Cody HS 3rd. Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment? Cancer. 2010 Apr 15;116(8):1987-91. PubMed PMID: 20151427.
37. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Reich LM, Bosl GJ, Motzer RJ. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010 Apr 1;28(10):1706-13. Epub 2010 Mar 1. Erratum in: J Clin Oncol. 2010 Dec 1;28(34):5126. PubMed PMID: 20194867.
38. Rudloff U, Brogi E, Reiner AS, Goldberg JI, Brockway JP, Wynveen CA, McCormick B, Patil S, Van Zee KJ. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg. 2010 Apr;251(4):583-91. PubMed PMID:20224381.
39. Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1064-72. Epub 2010 Mar 29. PubMed PMID: 20350793.
40. Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20;28(18):2982-8. Epub 2010 May 17.
Erratum in: J Clin Oncol. 2010 Aug 1;28(22):3670. PubMed PMID: 20479410.
41. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM, Dickler M, Hudis
CA, Jochelson M, McArthur HL. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol. 2010 Jul 1;28(19):3154-9. Epub 2010 Jun 1. PubMed PMID: 20516453.
42. Kumar S, Bramlage M, Jacks LM, Goldberg JI, Patil SM, Giri DD, Van Zee KJ. Minimal disease in the sentinel lymph node: how to best measure sentinel node micrometastases to predict risk of additional non-sentinel lymph node disease. Ann Surg Oncol. 2010 Nov;17(11):2909-19. Epub 2010 Jun 9. PubMed PMID: 20532987.
43. Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Morrow M, Gemignani ML. Determinants of outcome in elderly patients with positive sentinel lymph nodes. Am J Surg. 2011 Jun;201(6):734-40. Epub 2010 Jul 8. PubMed PMID: 20619395.
44. Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010 Aug 10;28(23):3762-9. Epub 2010 Jul 12. PubMed PMID: 20625132.
45. Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2010 Aug 14. [Epub ahead of print] PubMed PMID: 20711632.
46. Pugliese M, Stempel M, Patil S, Hsu M, Ho A, Traina T, Morrow M, Cody H 3rd, Gemignani ML. The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer. Am J Surg. 2010 Sep;200(3):368-73. PubMed PMID: 20800716.
47. Arora N, King TA, Jacks LM, Stempel MM, Patil S, Morris E, Morrow M. Impact of breast density on the presenting features of malignancy. Ann Surg Oncol. 2010 Oct;17(Suppl 3):211-8. Epub 2010 Sep 19. PubMed PMID: 20853035.
48. Drullinsky P, Sugarman SM, Fornier MN, D’Andrea G, Gilewski T, Lake D, Traina T, Wasserheit-Lieblich C, Sklarin N, Atieh-Graham D, Mills N, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clin Breast Cancer. 2010 Dec 1;10(6):440-4. PubMed PMID: 21147686.
49. Neuman HB, Patil S, Fuzesi S, Wong WD, Weiser MR, Guillem JG, Paty PB, Nash GM, Temple LK. Impact of a temporary stoma on the quality of life of rectal cancer patients undergoing treatment. Ann Surg Oncol. 2011 May;18(5):1397-403. Epub 2010 Dec 3. PubMed PMID: 21128000.
50. Marti JL, Dauer LT, Stempel M, Patil S, Kaplan JB, Montgomery LL. Cumulative imaging radiation exposure following breast-conservation therapy. Ann Surg Oncol. 2011 Jan;18(1):104-8. Epub 2010 Aug 18. PubMed PMID: 20717730.
51.  Van Zee KJ, Rudloff U, Brogi E, Patil S.  Reply to C. Manzouni et al.  J Clin Oncol. Jan 10, 2011:e45-e46.
52.  Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2011 Feb;22(2):295-300. Epub 2010 Jul 25. PMID: 20657034
53.  McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser MM, Paulson M, Traina TA, Patil S, Zhou Q, Steingart RM, Dang CT, Morrow M, Cordeiro P, Fornier MN, Park JW, Seidman AD, Lake D, Gilewski TA, Theodoulou M, Modi S, D’Andrea G, Sklarin N, Robson ME, Moynahan ME, Sugarman S, Sealey J, Laragh JH, Merali C, Norton L, Hudis C, Dicker MN. A feasibility study of bevacizumab plus dose-dense doxorubicin cyclophosphamide (ac) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15;17(10):3398-407. Epub 2011 Feb 24. PubMed PMID: 21350003.
54.  King TA, Gurevich I, Sakr T, Patil S, Stempel M, Morrow M.  Occult malignancy in patients undergoing contralateral prophylactic mastectomy.  Ann Surg. 2011 Jul;254(1)2-7. Epub 2011 Mar 2. PMID: 21372684.
55.  Bosl GJ, Patil S. Reply to S. Stenning et al and J. Lipshitz.  J Clin Oncol 2011 Nov 1;29(31):4211-4212.
56.  Bosl GJB, Patil SM.  Carboplatin in clinical stage I seminoma: too much and too little at the same time.  J Clin Oncol. 2011 Mar 10;29(8):949-52. Epub 2011 Jan 31. PMID: 21282532.
57.  Morris PG, Chen C, Steingart RM, Fleisher M, Lin NU, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler MN, McArthur HL, Winer EP, Norton L, Hudis C, Dang CT. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011 may 15;17(10):3490-9. Epub 2011 Mar 3. PubMed PMID: 21372222.
58.  Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer. 2011 Sep 15;117(18):4125-31. Epub 2011 Mar 8. doi: 10.1002/cncr.25992. PubMed PMID: 21387266.
59.  Brogi E, Murphy CG,  Johnson ML, Conlin A, Hsu M,  Patil S, Akram M,  NehhozinaT, Jhaveri KL, Hudis CA, Seidman AD.  Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Ann Oncol. 2011 Dec;22(12)2597-603. Epub 2011 March 21. PMID: 21427063
60.  King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.  J Clin Oncol. 2011 Jun 1;29(16):2158-64. Epub 2011 Apr 4. PMID: 21464413.
61.  Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D’Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma M, Patil S, Norton L, Hannah AL, Hudis CA. HSP90 Inhibition is Effective in Breast Cancer: A Phase 2 trial of tanespimycin (17aag) plus trastuzumab in patients with her2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011 Aug 1;17(15):5132-9. Epub 2011 May 10. PMID:21558407.
62.  Kalinsky K, Heguy A, Bhanot U, Patil S, Moynahan ME. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.  Breast Cancer Res Treat. 2011 Sep;129(2):635-43. doi: 10.1007/s10549-011-1601-4. Epub 2011 May 27. PubMed PMID: 21617917.
63.  Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol. 2011 Oct;34(5):454-9. PMID: 21127411
64.  Gucalp A, Sparano J, Caravelli J, Santamauro, Patil S, Abbruzzi A, Pelligrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis CA, Traina TA. Phase II trial of saracatinib (azd0530), an oral src-inhibitor for the treatment of patients with hormone receptor negative metastatic breast cancer.  Clin Breast Cancer. 2011 Oct;11(5):306-11. Epub 2011 May 3. PubMed PMID: 21729667.
65.  McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 2011 Dec 15;117(24):5461-8.  Epub 2011 Jun 16. doi:10.1002/cncr.26171. PubMed PMID: 21681735.
66.  Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, Bajorin DF, Bosl GJ, Motzer RJ. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. Cancer. 2012; Feb 15;118(4):981-6. Epub 2011 Jul 26. doi: 10.1002/cncr.26375. PubMed PMID: 21792865.
67.  Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2012 Jan 15;118(2):493-9. Epub 2011 May 19. doi: 10.1002/cncr.26191. PubMed PMID: 21598239.
68.  Weber WP, Barry M, Stempel MM, Junqueira MJ, Eaton AA, Patil SM, Morrow M, Cody HS 3rd. A 10-Year trend analysis of sentinel lymph node frozen section and completion axillary dissection for breast cancer: are these procedures becoming obsolete? Ann Surg Oncol. 2012 Jan; 19(1):225-32. Epub 2011 Jun 7. PubMed PMID: 21647763.
69.  Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil SM, Motzer RJ. Phase I trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012 Apr 1;118(7):1868-76. Epub 2011 Sep 6. doi: 10.1002/cncr.26429. PubMed PMID: 21898375.
70.  Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D’Andrea G, Lake D, Norton L, Hudis CA, Traina TA. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2012 jan;131(1):111-6. Epub 2011 Sep 4. PubMed PMID: 21898114.
71.  Blinder VS, Patil S, Thind A, Diamant A, Hudis C, Basch EM, Maly R. Return to work in low-income latina and non-latina white breast cancer survivors: a three-year longitudinal study.  Cancer. 2012 March 15;118(6):1664-74. Epub 2011 Aug 25. doi: 10.1002/cncr.26478. PubMed PMID: 22009703.
72.  Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer. 2012 April 15;118(8):1982-8. Epub 2011 Sep 1. doi: 10.1002/cncr.26484. PubMed PMID: 21887681.
73.  Murphy CG, Mallam D, Stein S, Patil S, Howard J, Sklarin N, Hudis CA, Gemignani ML, Seidman AD. Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer. 2012 Jul 1;118(13):3254-9. Epub 2011 Nov 15. doi: 10.1002/cncr.26654. PubMed PMID: 22086863.
74.  Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN. Serum N-Telopeptide and bone specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases J Oral Maxillofac Surg. 2012 Dec; 70(12):2768-75. Epub 2012 Feb 11. PubMed PMID: 22330331.
75.  Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, Traina T, McCormick B, Powell SN, Robson ME. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer. 2012 Oct 15;118(20):4944-52. Epub 2012 Mar 5. doi: 10.1002/cncr.27480. PubMed PMID: 22392492.
76.  Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN.  Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J. 2012 Jul-Aug;18(4):345-50. Epub 2012 May 21. doi: 10.1111/j.1524-4741.2012.01246.x. PMID: 22607041.  
77.  Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ.  Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib versus interferon-alfa. Br J Cancer. 2012 May 8;106(10):1587-90. doi: 10.1038/bjc.2012.149 . PubMed PMID: 22568998.
78.  Wen YH, Ho A, Patil S, Akram M, Catalano J, Eaton A, Norton L, Benezra R, Brogi E.  Id4 protein is highly expressed in triple negative breast carcinomas: possible implications for brca1 downregulation.  Breast Cancer Res Treat. 2012 Aug;135(1):93-102. Epub 2012 Apr 27. PMID:22538771.
79.  Damast S, Alektiar KM, Goldfarb S, Eaton A, Patil S, Mosenkis J, Bennett A, Atkinson T, Jewell E, Leitao M, Barakat R, Carter J, Basch E. Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e187-93. Epub 2012 May 8. PubMed PMID: 22572074.
80. Van Zee KJ, Patil S. Validation of a nomogram for predicting risk of local recurrence for ductal carcinoma in situ. J Clin Oncol. 2012 Sep 1;30(25):3143-4. Epub 2012 Jul 23. PubMed PMID: 22826276.
81.  Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T,  Atkins M, Bukowski R, Motzer RJ. Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international dataset of clinical trials. J Urol. 2012 Dec;188(6):2095-100. Epub 2012 Oct 18. doi:10.1016/j.juro.2012.08.026. PubMed PMID: 23083849.
82.  Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA. Frequent mutational activation of the pi3k-akt pathway in trastuzumab-resistant breast cancer. Clin Cancer Res. 2012 Dec 15;18(24):6784-91. doi: 10.1158/1078-0432.CCR-12-1785. Epub 2012 Oct 23. PubMed PMID: 23092874; PubMed Central PMCID: PMC3525734.
83.  Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard J, Larson S, Hudis CA, McArthur HL, Jochelson MS.  Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.  Cancer. 2012 Nov 15;118(22):5454-62. doi: 10.1002/cncr.27579. Epub 2012 Apr 19.  PMID: 22517371.
84.  Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer. 2013 April 1;119(7):1344-8. Epub 2012 Nov 16. doi: 10.1002/cncr.27842. PubMed PMID: 23165893.
85.  Kapoor NS, Eaton A, King TA, Patil S, Stempel M, Morris E, Brogi E, Morrow M.  Should breast density influence patient selection for breast-conserving surgery? Ann Surg Oncol. 2013 Feb;20(2):600-6. Epub 2012 Sep 1. PubMed PMID: 22941162.
86. Choi DX, Eaton AA, Olcese C, Patil S, Morrow M, Van Zee KJ. Blurry boundaries: do epithelial borderline lesions of the breast and ductal carcinoma in situ have similar rates of subsequent invasive cancer? Ann Surg Oncol. 2013 Apr;20(4):1302-10. Epub 2012 Nov 19. PubMed PMID: 23161115.
87.  Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ.  Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013 Sep;11(3):297-302. doi: 10.1016/j.clgc.2013.04.001. Epub 2013 May 24. PubMed PMID: 23707221
88.  Feldman DR, Voss MH, Jacobsen EP, Jia X, Suarez JA, Turkula S, Sheinfeld J, Bosl GJ, Motzer RJ, Patil S.  Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013 Jul 15;119(14):2574-81. doi: 10.1002/cncr.28025. Epub 2013 Apr 19. PubMed PMID: 23606402.
89.  Perez CA, Zumsteg ZS, Gupta G, Morrow M, Arnold B, Patil SM, Traina TA, Robson ME, Wen YH, McCormick B, Powell SN, Ho AY. Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast Cancer Res Treat. 2013 Jun;139(2):497-506. doi: 10.1007/s10549-013-2550-x. Epub 2013 May 5. PubMed PMID: 23645006.
90.  Blinder V, Patil S, Eberle C, Griggs J, Maly RC.  Early predictors of not returning to work in low-income breast cancer survivors: a 5-year longitudinal study.  Breast Cancer Res Treat. 2013 Jul;140(2):407-16. doi: 10.1007/s10549-013-2625-8. Epub 2013 Jul 25. PubMed PMID: 23884596.
91.  Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell KL, Rugo H, Nabell L, Forero-Torres A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri D, Patil S, Feigin KN, Hudis CA, Traina TA. Phase II trial of bicalutamide in patients with androgen receptor positive, hormone receptor negative metastatic breast cancer. Clin Cancer Res. 2013 Oct 1;19(19):5505-12. Epub 2013 Aug 21. PubMed PMID: 23965901.
92.  Gemignani ML, Patil S, Seshan VE, Sampson M, Humm JL, Lewis JS, Brogi E, Larson SM, Morrow M, Pandit-Taskar N.  Feasibility and predictability of perioperative pet and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med. 2013 Oct;54(10)1697-702. Epub 2013 Aug 22.  PubMed PMID: 23970364.
93.  Moo TA, McMillan R, Lee M, Stempel M, Patil S, Ho A, El-Tamer M. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes. Ann Surg Oncol. 2013 Oct;20(10):3169-74.  doi: 10.1245/s10434-013-3117-0. Epub 2013 Aug 22. PubMed PMID: 23975289.
94.  Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 2013 Nov 15;119(22):3943-51. Epub 2013 Aug 26. doi: 10.1002/cncr.28284. PubMed PMID: 24037735.
95.  King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M.  Is there a role for routine screening MRI in women with LCIS?  Breast Cancer Res Treat. 2013 Nov;142(2):445-53. doi: 10.1007/s10549-013-2725-5. Epub 2013 Oct 19.  PMID: 24141896.
96.  Sugaya L, de Alcantara Filho PR, Mota BS, Patil SM, Van Zee KJ, Bevilacqua JLB. A comparison of breast surgeon and nomogram-generated risk predictions of sentinel and non-sentinel node metastases. J Cancer Ther 2013; 4(7):1-6.
97. Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, Larson S, Hudis CA, Jochelson MS.  Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013 Oct;2(5):725-33. Epub 2013 Sept 12.
98.  Dengel LT, Van Zee KJ, King TA, Stempel M, Cody HS, El-Tamer M, Gemignani ML, Sclafani LM, Sacchini VS, Heerdt AS, Plitas G, Junqueira M, Capko D, Patil S, Morrow M. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol. 2014 Jan;21(1):22-7. Epub 2013 Aug 22. PubMed PMID: 23975314.
99.  Moo TA, Choi L, Culpepper C, Olcese C, Heerdt A, Sclafani L, King TA, Reiner AS, Patil S, Brogi E, Morrow M, Van Zee KJ. Impact of margin assessment method on positive margin rate and total volume excised. Ann Surg Oncol. 2014 Jan;21(1):86-92. Epub 2013 Sep 18. PubMed PMID: 24046114.
100.  Houldsworth J, Guttapalli A, Thodima V, Yan XJ, Mendiratta G, Zielonka T, Nanjangud G, Chen W, Patil S, Mato A, Brown JR, Rai K, Chiorazzi N, Chaganti RS.  Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Apr;55(4):920-8. Epub 2013 Nov 12. PubMed PMID: 24047479.
101.  Bokacheva L, Kaplan JB, Giri DD, Patil S, Gnanasigamani M, Nyman CG, Deasy JO, Morris EA, Thakur SB.  Intravoxel incoherent motion diffusion-weighted MRI at 3.0 T differentiates malignant breast lesions from benign lesions and breast parenchyma.  J Magn Reson Imaging. 2014 Oct;40(4):813-23. Epub 2013 Nov 22. doi: 10.1002/jmri.24462. PubMed PMID: 24273096.
102.  Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB. Causes of death in long-term survivors of head and neck cancer. Cancer. 2014 May 15;120(10):1507-13. doi: 10.1002/cncr.28588. Epub 2014 Feb 22. PubMed PMID: 24863390.
103. Sim HW, Morris PG, Patil S, Khasraw M. Brain metastases in breast cancer. Expert Rev Anticancer Ther. 2014 Feb;14(2):173-83. Epub 2013 Dec 2. PubMed PMID: 24308683.
104. Pilewskie M, Ho A, Orell E, Stempel M, Chen Y, Eaton A, Patil S, Morrow M. Effect of Margin Width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy. Ann Surg Oncol. 2014 Apr;21(4):1209-14. Epub 2013 Dec 11. PubMed PMID: 24327132.
105. Pilewskie M, Olcese C, Eaton A, Patil S, Morris E, Morrow M, Van Zee KJ. Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. Ann Surg Oncol. 2014 May;21(5):1552-60. Epub 2014 Jan 3. PubMed PMID: 24385207.
106. Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh J, Molina AM, Patil SM, Motzer RJ.  Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol. 2014 Mar;25(3):663-8. Epub 2014 Jan 23. PubMed PMID: 24458473.
107. Sweldens C, Peeters S, van Limbergen E,  Janssen H, Laenen A, Patil SM, Van Zee, KJ, Weltens C.  Local relapse after breast conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram. Caner J 2014 Jan-Feb;20(1):1-7.  PubMed PMID: 24445756.
108. Moo TA, McMillan R, Lee M, Stempel M, Ho A, Patil S, El-Tamer M. Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes. Ann Surg Oncol. 2014 May;21(5):1569-74. doi: 10.1245/s10434-014-3488-x. Epub 2014 Feb 1. PubMed PMID:  24488216.
109. Damast S, Alektiar K, Eaton A, Gerber NK, Goldfarb S, Patil S, Jia R, Leitao M, Carter J, Basch E. Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer. Ann Surg Oncol. 2014 Aug;21(8):2740-54. Epub 2014 Mar 12. PubMed PMID: 24619493.
110. Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D’Andrea G, Lim K, Reddington L, Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 2014  Jun;14(3):154-60. doi: 10.1016/j.clbc.2013.12.012. Epub 2013 Dec 28. PubMed PMID: 24512858.
111. Feldman DR, Iyer G, Van Alstine L, Patil S, Al-Ahmadie HA, Reuter VE, Bosl GJ, Chaganti RS, Solit DB. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res. 2014 Jul 15;20(14):3712-20. Epub 2014 May 8. PubMed PMID: 24812411.
112. Sung JS, Li J, Costa GD, Patil S, Van Zee KJ, Dershaw DD, Morris EA. Preoperative breast MRI for early-stage breast cancer: effect on surgical and long-term outcomes. AJR Am J Roentgenol. 2014 Jun;202(6):1376-82. doi: 10.2214/AJR.13.11355. PubMed PMID: 24848838.
113. Bastos DA, Molina AM, Hatzoglou V, Jia X, Velasco S, Patil S, Voss MH, Feldman DR, Motzer RJ.  Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. Clin Genitourin Cancer. 2014 Jun 8. pii: S1558-7673(14)00103-7. doi: 10.1016/j.clgc.2014.06.002. [Epub ahead of print]  PubMed PMID: 25023939
114. Ugras S, Stempel M, Patil S, Morrow M. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol. 2014 Nov;21(12)3780-6. Epub 2014 Jun 21. PubMed PMID: 24952028.
115. Oppong BA, Pharmer LA, Oskar S, Eaton A, Stempel M, Patil S, King TA. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med. 2014 Aug;3(4):1025-34. Epub 2014 Jun 18. doi: 10.1002/cam4.259.  PubMed PMID: 24944108.
116. Manning AT, Eaton A, Azu M, Sampson M, Patil S, Godfrey D, Beesen AA, Liberman L, Gemignani ML. Breast cancer screening at the Breast Examination Center of Harlem. Ann Surg Oncol. 2014 Dec 2. [Epub ahead of print]
117.  Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, Ho AY, Reis-Filho JS, Weigelt B, Norton L, Adusumilli PS, Wen HY. Mesothelin expression in triple negative breast carcinomas correlates significantly with Basal-like phenotype, distant metastases and decreased survival. PLoS One. 2014 Dec 15;9(12):e114900. doi: 10.1371/journal.pone.0114900. eCollection 2014. PubMed PMID: 25506917.
118.  Dang C, Iyengar N, Datko F, D’Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C. Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2014 Dec 29. pii: JCO.2014.57.1745. [Epub ahead of print].

 

My Events